Lu-DWJ155 is a lutetium-177 radiolabeled agent, [177Lu]Lu-DWJ155, studied in breast cancer, non-small cell lung cancer, gastric or gastroesophageal junction cancer, and bladder cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.